Business Wire

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers ...

TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis ...
VentureBeat

Ai2’s Olmo 3 family challenges Qwen and Llama with efficient, open reasoning and customization

The Allen Institute for AI (Ai2) hopes to take advantage of an increased demand for customized models and enterprises seeking more transparency from AI models with its latest release. Ai2 made the ...
Business Wire

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common ...
Seeking Alpha

Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript

Thank you for standing by. My name is Dina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer Bio Inc. PROSERA Phase 3 Topline Results Call. ...
Nasdaq

Vera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint

Vera Therapeutics, Inc. announced that its ORIGIN Phase 3 trial for atacicept, a treatment for immunoglobulin A nephropathy (IgAN), achieved its primary endpoint by demonstrating a significant ...